[{"address1": "863 Mitten Road", "address2": "Suite 102", "city": "Burlingame", "state": "CA", "zip": "94010", "country": "United States", "phone": "650 900 4520", "website": "https://www.corvuspharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.", "fullTimeEmployees": 29, "companyOfficers": [{"maxAge": 1, "name": "Dr. Richard A. Miller M.D.", "age": 72, "title": "Co-Founder, President, CEO & Chairman of the Board", "yearBorn": 1951, "fiscalYear": 2022, "totalPay": 306000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter A. Thompson FACP, M.D.", "age": 63, "title": "Co-Founder & Independent Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 47000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leiv  Lea", "age": 69, "title": "Chief Financial Officer", "yearBorn": 1954, "fiscalYear": 2022, "totalPay": 388731, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William Benton Jones Ph.D.", "age": 57, "title": "Senior Vice President of Pharmaceutical Development", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 346419, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James T. Rosenbaum M.D.", "title": "Senior Vice President of Research", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.25, "open": 2.26, "dayLow": 2.17, "dayHigh": 2.42, "regularMarketPreviousClose": 2.25, "regularMarketOpen": 2.26, "regularMarketDayLow": 2.17, "regularMarketDayHigh": 2.42, "beta": 1.039, "forwardPE": -4.9183674, "volume": 248574, "regularMarketVolume": 248574, "averageVolume": 224385, "averageVolume10days": 266200, "averageDailyVolume10Day": 266200, "bidSize": 800, "askSize": 1400, "marketCap": 118183032, "fiftyTwoWeekLow": 0.607, "fiftyTwoWeekHigh": 4.19, "fiftyDayAverage": 1.5542, "twoHundredDayAverage": 1.84621, "currency": "USD", "enterpriseValue": 87704984, "floatShares": 36878485, "sharesOutstanding": 49038600, "sharesShort": 1303196, "sharesShortPriorMonth": 1792120, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.026600001, "heldPercentInsiders": 0.03887, "heldPercentInstitutions": 0.39975, "shortRatio": 6.6, "shortPercentOfFloat": 0.0353, "impliedSharesOutstanding": 49038600, "bookValue": 0.903, "priceToBook": 2.6688817, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -30192000, "trailingEps": -0.64, "forwardEps": -0.49, "enterpriseToEbitda": -3.813, "52WeekChange": 1.653302, "SandP52WeekChange": 0.20000207, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CRVS", "underlyingSymbol": "CRVS", "shortName": "Corvus Pharmaceuticals, Inc.", "longName": "Corvus Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1458739800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "956d43b5-68cb-3c6d-b466-9b34fd9537d2", "messageBoardId": "finmb_279359732", "gmtOffSetMilliseconds": -18000000, "currentPrice": 2.41, "targetHighPrice": 12.0, "targetLowPrice": 3.5, "targetMeanPrice": 7.88, "targetMedianPrice": 8.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 32168000, "totalCashPerShare": 0.656, "ebitda": -23001000, "totalDebt": 1690000, "quickRatio": 4.414, "currentRatio": 4.534, "debtToEquity": 3.816, "returnOnAssets": -0.21938999, "returnOnEquity": -0.55412996, "freeCashflow": -18238250, "operatingCashflow": -26315000, "financialCurrency": "USD", "trailingPegRatio": null}]